BioSpace News Archive

Foundational study with plans to address multiple types of agitation associated with dementia

Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition of Full Clinical Results in 1H2021 to Support Full Approval under Fast Track Designation

Bio-Techne Corporation announced that the Atlanta Biologicals portfolio of serum and media will be rebranded as R&D Systems.

Synthetic Biologics, Inc. announced the receipt of official meeting minutes from the U.S. Food and Drug Administration following a Type C meeting held on December 2, 2019 at the Company’s request to discuss the development of SYN-004 in allogeneic hematopoietic cell transplant recipients who are administered intravenous beta-lactam antibiotics in response to fever.

New campus extends international ecosystem of world leader in orthopedics & rheumatology

Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA has established coverage for its solid tumor molecular profile.

New IP Protection Creates Barriers to Entry and Supports the Company’s Business Opportunities

Following the additional U.S. Food and Drug Administration clearance for its Cryoablation Technology, IceCure Medical Ltd., an Israeli medical device company, developers of a non-surgical Liquid Nitrogen cryoablation technology to destroy benign and cancerous tumors by freezing, plans to significantly extend its U.S. operations in target markets for indications with existing CPT codes and reimbursement.

Innovation announced several changes to the company’s leadership team.

An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment